About Quantason
Quantason, LLC has developed a revolutionary, next-generation bi-modal (US/IDUS™) technology which fundamentally changes the utilization of conventional ultrasound both as a modality for diagnostic imaging and as an active screening method. Quantason's technology expands the capabilities of conventional ultrasound systems by combining anatomical 2-D imaging with proprietary real-time stimulation paradigms to image, detect, locate in 3-D, and classify micron-size target(s) based on their response signature(s). Quantason's patent-pending technology is sensitive to tissue characteristics and material properties which are clinically associated with disease states, such as breast cancer markers, which may not be visible in traditional ultrasonic and mammographic images. It allows for detecting and consequently, imaging of micron-size target(s) previously conceived to be outside of conventional ultrasound capabilities. Quantason's technology is compatible with both automated/hands-free as well as hand-held ultrasound scanners. This ultrasound-based technology is free of harmful ionizing-radiation, is convenient to patients, time effective, reimbursable, and cost-effective. Targeted applications include breast screening, in-situ drug delivery, precision biopsy guidance, intra-body navigations, and other non-medical applications.